CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Net Inc. Y/Y Annual
Protalix Biotherapeutics inc   (PLX)
Other Ticker:  
 
 

PLX's Net Income Growth by Quarter and Year

Protalix Biotherapeutics Inc 's Net Income results by quarter and year




PLX Net Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - -6.04 -3.74 -6.67
III Quarter September - -1.85 -3.57 -4.20
II Quarter June -2.20 19.34 -5.33 -11.24
I Quarter March -4.60 -3.13 -2.29 -5.48
FY   -6.80 8.32 -14.93 -27.59



PLX Net Income second quarter 2024 Y/Y Growth Comment
Protalix Biotherapeutics inc in the second quarter 2024 recorded net loss of $ -2.20 millions.

Looking into second quarter 2024 results within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Net Income growth. While Protalix Biotherapeutics Inc ' s Net Income no change of % ranks overall at the positon no. 497 in the second quarter 2024.


PLX Net Income ( Y/Y Growth %) 2024
 2023 2022 2021
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Protalix Biotherapeutics Inc 's second quarter 2024 Net Income $ -2.20 millions PLX's Income Statement
Protalix Biotherapeutics Inc 's second quarter 2023 Net Income $ 19.34 millions Quarterly PLX's Income Statement
New: More PLX's historic Net Income Growth >>


PLX Net Income (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -


Compare PLX Profitability >> Back to PLX Growth rate Comparisons >>


Net Income second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #47
Overall #497

Net Income Y/Y Growth Statistics
High Average Low
-150.6 % -239.35 % -274.64 %
(Dec 31 2016)   (Dec 31 2017)
Net Income second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #47
Overall #497
Net Income Y/Y Growth Statistics
High Average Low
-150.6 % -239.35 % -274.64 %
(Dec 31 2016)   (Dec 31 2017)

Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Protalix Biotherapeutics Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PLX's II. Quarter Q/Q Net Income Comment
Although Protalix Biotherapeutics inc in the II. Quarter 2024 revealed net loss of $ -2.20 millions, it should be said, that current results point to improvement relative to the -4.60 millions in the first quarter.

Within Biotechnology & Pharmaceuticals industry Protalix Biotherapeutics inc achieved highest sequential Net Income growth. While Protalix Biotherapeutics Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PLX's II. Quarter Q/Q Net Income Comment
Even if Protalix Biotherapeutics inc in the II. Quarter 2024 admitted net loss of $ -2.20 millions, management mentioned, that current results point to recovery compare to the -4.60 millions in the first quarter.

Within Biotechnology & Pharmaceuticals industry Protalix Biotherapeutics inc achieved highest sequential Net Income growth. While Protalix Biotherapeutics Inc 's Net Income growth quarter on quarter, overall rank is .


Protalix Biotherapeutics Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Net Income 12 Months Ending $ -14.69 $ 6.85 $ 8.31 $ 10.62 $ 8.90
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - -17.61 % -21.7 % 19.27 % -
Seq. Net Income Growth (TTM) Overall Ranking # 497 # 484 # 472 # 652 # 0

New: More PLX's historic Net Income Growth >>



Cumulative Net Income growth Comment
Protalix Biotherapeutics Inc realized trailing twelve months net loss of $ -15 millions, in the Jun 30 2024, compare to Net Income of $ 9 millions a year ago.

Protalix Biotherapeutics inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
-150.6 %
-239.35 %
-274.64 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 47
S&P 500 # 497
Cumulative Net Income growth Comment
Protalix Biotherapeutics Inc realized trailing twelve months net loss of $ -15 millions, in the Jun 30 2024, compare to Net Income of $ 9 millions a year ago.

Protalix Biotherapeutics inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
-150.6 %
-239.35 %
-274.64 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 47
S&P 500 # 497




Other Net Income Growth
Biotechnology & Pharmaceuticals Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
PLX's Net Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for PLX's Competitors
Net Income Growth for Protalix Biotherapeutics Inc 's Suppliers
Net Income Growth for PLX's Customers

You may also want to know
PLX's Annual Growth Rates PLX's Profitability Ratios PLX's Asset Turnover Ratio PLX's Dividend Growth
PLX's Roe PLX's Valuation Ratios PLX's Financial Strength Ratios PLX's Dividend Payout Ratio
PLX's Roa PLX's Inventory Turnover Ratio PLX's Growth Rates PLX's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Net Income for the quarter ending Jun 30 2024
Biogen Inc -1.63%$ -1.635 millions
Embecta Corp -3.29%$ -3.289 millions
Quest Diagnostics Inc-3.61%$ -3.614 millions
Abbott Laboratories-5.31%$ -5.309 millions
Zoetis Inc -6.87%$ -6.866 millions
Idexx Laboratories Inc-9.34%$ -9.337 millions
Prestige Consumer Healthcare Inc -11.89%$ -11.893 millions
Align Technology inc -13.64%$ -13.639 millions
National Research Corporation-15.10%$ -15.097 millions
Dariohealth Corp -17.94%$ -17.938 millions
Bristol myers Squibb Company-18.92%$ -18.922 millions
Organon and Co -19.42%$ -19.421 millions
U S Physical Therapy Inc-21.21%$ -21.206 millions
Fonar Corporation-25.01%$ -25.010 millions
Pacira Biosciences inc -26.69%$ -26.693 millions
Privia Health Group Inc -27.00%$ -26.997 millions
West Pharmaceutical Services Inc -28.24%$ -28.240 millions
Neurocrine Biosciences Inc -31.94%$ -31.937 millions
Abbvie Inc -32.26%$ -32.264 millions
Lifevantage Corp-33.62%$ -33.622 millions
Lantheus Holdings Inc -34.06%$ -34.057 millions
Viemed Healthcare Inc -36.61%$ -36.609 millions
Vaso Corporation-44.26%$ -44.257 millions
Nature s Sunshine Products inc -44.42%$ -44.415 millions
Royalty Pharma Plc-44.67%$ -44.675 millions
Globus Medical Inc -44.97%$ -44.968 millions
Amgen Inc -45.90%$ -45.903 millions
Elite Pharmaceuticals Inc -46.07%$ -46.070 millions
Surgery Partners Inc -50.78%$ -50.780 millions
Radnet Inc -52.29%$ -52.294 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com